Previous close | 2.7500 |
Open | 2.7500 |
Bid | 2.6500 |
Ask | 4.2000 |
Strike | 9.00 |
Expiry date | 2024-05-17 |
Day's range | 2.7500 - 2.7500 |
Contract range | N/A |
Volume | |
Open interest | 18 |
Explore key financial outcomes and strategic updates from Inovio Pharmaceuticals Inc's first quarter of 2024, signaling robust progress and operational efficiency.
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the "Inducement Plan").